What is LOPJLB’s current signal on LEGN?

LOPJLB’s latest quantitative signal on Legend Biotech Corporation (LEGN) is SELL in a RECOVERY regime. Signals are updated daily.

What market regime is LEGN in?

Legend Biotech Corporation (LEGN) is currently classified in the RECOVERY HMM market regime on LOPJLB.

What does Legend Biotech Corporation (LEGN) do?

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of mu…

Legend Biotech Corporation (LEGN)

COMPARE

Healthcare · Biotechnology · NASDAQ · US

$18.62-0.48%Close

SELLRECOVERY · day 5

Company news

globenewswire.com · 11d ago

Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma

defenseworld.net · 16d ago

Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Stock Has Consensus Price Target of $53.14 According to Analysts

globenewswire.com · 17d ago

Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion

reuters.com · 27d ago

Legend Biotech taps Novartis veteran Zhang as CEO

globenewswire.com · 27d ago

Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer

wsj.com · 27d ago

Legend Biotech is tapping a Novartis executive to run the cell-therapy maker, ending a nearly two-month search that began when former CEO Ying Huang resigned in July

globenewswire.com · 32d ago

Legend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual Meeting

globenewswire.com · 41d ago

Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference

247wallst.com · 61d ago

Here Are Wednesday’s Top Wall Street Analyst Research Calls: The Gap, Genmab, Hilton Worldwide, Intuitive Surgical, Marriott International, Merck, Novo Nordisk, Okta, and More

seekingalpha.com · 62d ago

Legend Biotech Corporation (LEGN) Q2 2026 Earnings Call Transcript

247wallst.com · 62d ago

Legend Biotech Gains 6% on Q2 Earnings Beat as Adjusted EPS Doubles Consensus

marketbeat.com · 62d ago

Legend Biotech Q2 Earnings Call Highlights

defenseworld.net · 76d ago

Legend Biotech (NASDAQ:LEGN) Shares Gap Down After Analyst Downgrade

globenewswire.com · 77d ago

Legend Biotech Announces CEO Transition

seekingalpha.com · 80d ago

Legend Biotech: Why I'm Ready To Go Long Again

Market news & ticker search · RSS for LEGN

FAQ

What is LOPJLB’s current signal on LEGN?: LOPJLB’s latest quantitative signal on Legend Biotech Corporation (LEGN) is SELL in a RECOVERY regime. Signals are updated daily.
What market regime is LEGN in?: Legend Biotech Corporation (LEGN) is currently classified in the RECOVERY HMM market regime on LOPJLB.
What does Legend Biotech Corporation (LEGN) do?: Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of mu…

Legend Biotech Corporation (LEGN)

Key stats

Industry peers

Prediction markets

Company news

FAQ